The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...
Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
GlobalData on MSN9d
EC approves GSK’s Jemperli-chemo combo for endometrial cancerThe EC has approved GSK's Jemperli (dostarlimab) combined with chemotherapy for primary advanced or recurrent endometrial ...
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...
GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...
London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback